Beijing, March 11, 2022——InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that it will host a conference call to discuss the 2021 full year financial results and provide a corporate update at 9:00 a.m. Beijing time on March 23, 2022. Before the call, the Company will announce the financial results for the full year ended December 31, 2021.
Conference Call Information
InnoCare will host a conference call on March 23, 2022 at 9:00 a.m. Beijing time. Participants must register in advance of the conference call. Details are as follows:
Registration Link: https://goldmansachs.zoom.us/webinar/register/WN_JKhYhUVYS1W8HrlfBjzWsg
The call will be conducted in Chinese.
Please pre-register by clicking the above link before the call.
A replay will be available on the Company’s website at Investor Relations page.
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, New Jersey and Boston.